BMC Public Health Published: 2 February 2018 Abstract: Background The New South Wales (NSW) HIV Strategy 2016–2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly...
The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines
Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...
Two-drug HIV therapy just as effective as three-drug therapy
aidsmap/nam, 25 October 2016
SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen, researchers reported on Monday at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).
Read more here
UK report gives thumbs up to generic HIV drugs used as PrEP
A sexual health clinic in London has tested drug levels in users of generic PrEP medication bought online and found the drugs are genuine and effective.
Tests found adequate levels of both emtricitabine and tenofovir (used in PrEP medication Truvada) in patients’ blood, and no sample suggesting counterfeit drugs.
Read more here
See conference program here
London sexual health clinics step up their support for people buying PrEP online
nam/aidsmap, 29 January 2016 Several large sexual health clinics in London and Brighton have responded to the growing numbers of people importing PrEP medications from overseas by offering free safety monitoring to PrEP users. This is in a context of increasing frustration with the slowness of the official NHS process to approve PrEP – no decision will be made until June at the earliest. Read...
HIV drug resistance on the rise, pressure for new treatment development
The World Today, ABC
Posted Fri at 2:36pm
Key points:
Research of about 2,000 people in 36 countries shows rise in resistance to major HIV treatment drug
60 per cent of people found resistant in Africa, in Europe close to 20 per cent
Patients with resistance have to use less suitable, more expensive and toxic drugs
Read more or listen to audio here